Use of oral verapamil in long-term treatment of neonatal, paroxysmal supraventricular tachycardia. A pharmacokinetic study

U. de Vonderweid, A. Benettoni, D. Piovan, R. Padrini

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Efficacy and pharmacokinetics of verapamil were studied in two neonates affected by supraventricular paroxysmal tachycardia, under maintenance treatment with the drug. Verapamil proved to be fully effective in suppressing arrhythmic episodes at the daily doses of 1.5 mg/kg four times a day in case 1 and of 2 mg/kg in case 2. The results of plasma half-life of the drug, calculated in a dose interval, were 3.14 hr and 2.10 hr, respectively. In patient 2, doses <0.95 mg/kg four times a day did not produce detectable drug plasma levels, while a further stepwise increase of dose up to 2 mg/kg four times a day produced a steep rise in trough concentration. So, in view of this dose-concentration relationship, caution is recommended in adjusting verapamil oral dosage.

Original languageEnglish
Pages (from-to)581-584
Number of pages4
JournalInternational Journal of Cardiology
Volume6
Issue number5
DOIs
Publication statusPublished - 1984

Fingerprint

Paroxysmal Tachycardia
Supraventricular Tachycardia
Verapamil
Pharmacokinetics
Pharmaceutical Preparations
Half-Life
Therapeutics
Newborn Infant

Keywords

  • drug monitoring
  • neonatal tachycardia
  • pre-excitation syndrome

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Use of oral verapamil in long-term treatment of neonatal, paroxysmal supraventricular tachycardia. A pharmacokinetic study. / de Vonderweid, U.; Benettoni, A.; Piovan, D.; Padrini, R.

In: International Journal of Cardiology, Vol. 6, No. 5, 1984, p. 581-584.

Research output: Contribution to journalArticle

de Vonderweid, U. ; Benettoni, A. ; Piovan, D. ; Padrini, R. / Use of oral verapamil in long-term treatment of neonatal, paroxysmal supraventricular tachycardia. A pharmacokinetic study. In: International Journal of Cardiology. 1984 ; Vol. 6, No. 5. pp. 581-584.
@article{a125a2de3d244dceb6d78033137498da,
title = "Use of oral verapamil in long-term treatment of neonatal, paroxysmal supraventricular tachycardia. A pharmacokinetic study",
abstract = "Efficacy and pharmacokinetics of verapamil were studied in two neonates affected by supraventricular paroxysmal tachycardia, under maintenance treatment with the drug. Verapamil proved to be fully effective in suppressing arrhythmic episodes at the daily doses of 1.5 mg/kg four times a day in case 1 and of 2 mg/kg in case 2. The results of plasma half-life of the drug, calculated in a dose interval, were 3.14 hr and 2.10 hr, respectively. In patient 2, doses <0.95 mg/kg four times a day did not produce detectable drug plasma levels, while a further stepwise increase of dose up to 2 mg/kg four times a day produced a steep rise in trough concentration. So, in view of this dose-concentration relationship, caution is recommended in adjusting verapamil oral dosage.",
keywords = "drug monitoring, neonatal tachycardia, pre-excitation syndrome",
author = "{de Vonderweid}, U. and A. Benettoni and D. Piovan and R. Padrini",
year = "1984",
doi = "10.1016/0167-5273(84)90002-0",
language = "English",
volume = "6",
pages = "581--584",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "5",

}

TY - JOUR

T1 - Use of oral verapamil in long-term treatment of neonatal, paroxysmal supraventricular tachycardia. A pharmacokinetic study

AU - de Vonderweid, U.

AU - Benettoni, A.

AU - Piovan, D.

AU - Padrini, R.

PY - 1984

Y1 - 1984

N2 - Efficacy and pharmacokinetics of verapamil were studied in two neonates affected by supraventricular paroxysmal tachycardia, under maintenance treatment with the drug. Verapamil proved to be fully effective in suppressing arrhythmic episodes at the daily doses of 1.5 mg/kg four times a day in case 1 and of 2 mg/kg in case 2. The results of plasma half-life of the drug, calculated in a dose interval, were 3.14 hr and 2.10 hr, respectively. In patient 2, doses <0.95 mg/kg four times a day did not produce detectable drug plasma levels, while a further stepwise increase of dose up to 2 mg/kg four times a day produced a steep rise in trough concentration. So, in view of this dose-concentration relationship, caution is recommended in adjusting verapamil oral dosage.

AB - Efficacy and pharmacokinetics of verapamil were studied in two neonates affected by supraventricular paroxysmal tachycardia, under maintenance treatment with the drug. Verapamil proved to be fully effective in suppressing arrhythmic episodes at the daily doses of 1.5 mg/kg four times a day in case 1 and of 2 mg/kg in case 2. The results of plasma half-life of the drug, calculated in a dose interval, were 3.14 hr and 2.10 hr, respectively. In patient 2, doses <0.95 mg/kg four times a day did not produce detectable drug plasma levels, while a further stepwise increase of dose up to 2 mg/kg four times a day produced a steep rise in trough concentration. So, in view of this dose-concentration relationship, caution is recommended in adjusting verapamil oral dosage.

KW - drug monitoring

KW - neonatal tachycardia

KW - pre-excitation syndrome

UR - http://www.scopus.com/inward/record.url?scp=0021231338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021231338&partnerID=8YFLogxK

U2 - 10.1016/0167-5273(84)90002-0

DO - 10.1016/0167-5273(84)90002-0

M3 - Article

VL - 6

SP - 581

EP - 584

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 5

ER -